• dose
  • She agreed to a rechallenge test with paroxetine at a reduced dose of 10 mg. (bmj.com)
  • The most common dose-dependent side effects associated with treatment discontinuation in clinical trials for the treatment of premenstrual dysphoric disorder with controlled-release paroxetine 25 mg compared with 12.5 mg included nausea, somnolence, impaired concentration, dry mouth, dizziness, decreased appetite, sweating, tremor, and yawn. (drugs.com)
  • On June 28, 2013, the U.S. Food and Drug Administration approved low-dose paroxetine for the treatment of moderate-to-severe vasomotor symptoms such as hot flashes and night sweats associated with menopause. (wikipedia.org)
  • concentrations
  • In a study in which normal male subjects (n = 15) received 30 mg tablets daily for 30 days, steady-state paroxetine concentrations were achieved by approximately 10 days for most subjects, although it may take substantially longer in an occasional patient. (nih.gov)
  • To our knowledge, the only published report of postural hypotension associated with paroxetine relates to its increasing trimipramine concentrations when prescribed with trimipramine. (bmj.com)
  • clinically
  • Studies at clinically relevant doses in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets. (nih.gov)
  • selective
  • In vitro studies in animals also suggest that paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. (nih.gov)
  • tablets
  • Paroxetine tablets, USP are an orally administered psychotropic drug. (nih.gov)
  • The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days. (nih.gov)
  • occur
  • Constipation Vomiting Anxiety Nervousness Hypomania,[unreliable medical source][unreliable medical source] may occur in as many as 8% of patients being treated with paroxetine. (wikipedia.org)
  • Patients
  • SAN ANTONIO -- Breast cancer patients who took the antidepressant paroxetine during their course of tamoxifen therapy were up to 91% more likely to die from their disease than were those who did not take the two drugs together, according to a retrospective, population-based cohort study conducted in the Canadian province of Ontario. (thefreedictionary.com)
  • At six weeks, 71% of SJW patients, compared to 60% of paroxetine patients, showed a 50% or greater reduction in depressive symptoms. (thefreedictionary.com)
  • studies
  • In a meta-analysis of paroxetine from 4 studies done in healthy volunteers following multiple dosing of 20 mg/day to 40 mg/day, males did not exhibit a significantly lower C max or AUC than females. (nih.gov)